Drug Information

Drug General Information
Drug ID
D08YDT
Former ID
DIB009576
Drug Name
KAI-4169
Synonyms
Protein kinase C modulator (secondary hyperparathyroidism), KAI pharmaceuticals; Calcium-sensing receptor agonist (secondary hyperparathyroidism), KAI Pharmaceuticals
Drug Type
Small molecular drug
Indication Hyperparathyroidism [ICD9: 252.02, 588.81; ICD10:E21.1] Phase 2 [523864]
Company
KAI Pharmaceuticals Inc
Structure
Download
2D MOL

3D MOL
Formula
C38H73N21O10S2
PubChem Compound ID
71716572
PubChem Substance ID
164130399
Target and Pathway
Target(s) Extracellular calcium-sensing receptor Target Info Agonist [532354]
Pathway Interaction Database E-cadherin signaling in keratinocytes
Reactome G alpha (q) signalling events
G alpha (i) signalling events
Class C/3 (Metabotropic glutamate/pheromone receptors)
WikiPathways GPCRs, Class C Metabotropic glutamate, pheromone
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 523864ClinicalTrials.gov (NCT01576146) Open-label Study to Assess the Long-term Safety and Efficacy of AMG 416 (Also Known as KAI-4169) in Patients With Secondary Hyperparathyroidism. U.S. National Institutes of Health.
Ref 532354Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther. 2013 Aug;346(2):229-40.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.